araag2/HINT huggingface dataset:
Clinical trial NCT00482664 (phase 2, status: completed)
Conditions: sexual dysfunction, physiological
ICD codes: F52.8, F52.9
Drugs: cp-866,087, cp-866,087, cp-866,087, placebo
SMILES: CC[C@]1([C@H]2CN(CC3(O)CC4=CC=CC=C4C3)C[C@@H]12)C1=CC=CC(NS(C)(=O)=O)=C1, CC[C@]1([C@H]2CN(CC3(O)CC4=CC=CC=C4C3)C[C@@H]12)C1=CC=CC(NS(C)(=O)=O)=C1, CC[C@]1([C@H]2CN(CC3(O)CC4=CC=CC=C4C3)C[C@@H]12)C1=CC=CC(NS(C)(=O)=O)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  healthy pre-menopausal women

          -  primary female sexual arousal disorder causing distress

          -  on stable use of oral contraceptives

        Exclusion Criteria:

          -  any other significant disease causing Female Sexual Dysfunction including psychiatric
             disease

          -  subjects on drugs known to cause Female Sexual Dysfunction

          -  subjects who have given birth in the last 12 months or who are planning to become
             pregnant during the study
Clinical trial NCT01282255 (phase 2, status: completed)
Conditions: inflammation, rheumatoid arthritis
ICD codes: H01.9, H30.93, H05.00, H30.003, H30.013, H30.033, H30.103, M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: nnc109-0012, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Czech Republic: Age between 18 - 65 years (both inclusive)

          -  A diagnosis of RA made at least 3 months prior to trial start

          -  Active RA

          -  Methotrexate treatment (between 7.5 mg and 25 mg/week, both inclusive) for at least 12
             weeks with a stable dose for at least 4 weeks prior to trial start

          -  Female subjects must be willing to avoid pregnancy and breast feeding throughout this
             trial at least until 15 weeks following the last dose of trial medication

          -  Male subjects with partners of childbearing potential must be willing to use a highly
             effective contraception throughout trial incl. a 15 week follow up periode

        Exclusion Criteria:

          -  Known or suspected allergy to trial product or related products

          -  Body Mass Index (BMI) lower than 18.5 or higher than 35.0 kg/m^2

          -  Subjects with chronic inflammatory autoimmune disease other than RA (except secondary
             Sjögren's syndrome or stable hypothyroidism)
Clinical trial NCT01563536 (phase 2, status: completed)
Conditions: chronic hepatitis c infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: abt-267, abt-450, abt-333, ritonavir, ribavirin
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C(C=C1)[C@@H]1CC[C@H](N1C1=CC=C(C=C1)C(C)(C)C)C1=CC=C(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1, [H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCC\C=C/2)NC(=O)C1=CN=C(C)C=N1)OC1=NC2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)NS(=O)(=O)C1CC1, COC1=C(C=C(C=C1C1=CC2=CC=C(NS(C)(=O)=O)C=C2C=C1)N1C=CC(=O)NC1=O)C(C)(C)C, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female between the age of 18 and 70 years, inclusive, at time of enrollment.

          -  Subject has never received antiviral treatment for hepatitis C virus (HCV) infection.

          -  Body mass index (BMI) is ≥ 18 to < 38 kg/m^2. BMI is calculated as weight measured in
             kilograms (kg) divided by the square of height measured in meters (m).

          -  Chronic HCV genotype 1-infection for at least 6 months prior to study enrollment.

          -  Subject has plasma HCV RNA level > 10,000 IU/mL at screening

        Exclusion Criteria:

          -  History of severe, life-threatening or other significant sensitivity to any drug.

          -  Females who are or plan to become pregnant or breastfeeding or males whose partner is
             pregnant or planning to become pregnant.

          -  Recent history of drug or alcohol abuse that could preclude adherence to the protocol.

          -  Positive test result for hepatitis B surface antigen or anti-human immunodeficiency
             virus (HIV) antibodies.

          -  Any current or past clinical evidence of cirrhosis (e.g., ascites, esophageal
             varices), or a liver biopsy or FibroTest/aspartate aminotransferase to platelet ratio
             (APRI) or FibroScan® showing cirrhosis or extensive bridging fibrosis.
Clinical trial NCT01097070 (phase 2, status: completed)
Conditions: hiv-1 infection
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: bevirimat
SMILES: [H][C@]12[C@@H](CC[C@@]1(CC[C@]1(C)[C@]2([H])CC[C@]2([H])[C@@]3(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O)C(C)=C
Eligibility criteria:

        Inclusion Criteria:

          -  Have documentation of HIV-1 infection in their medical records (documentation of any
             prior plasma viremia is acceptable).

          -  Have a CD4+ lymphocyte count >/= 100 cells/mm3.

          -  Have a screening plasma HIV-1 RNA value, measured by the Roche Amplicor assay, of <400
             copies/mL.

          -  Be receiving an ARV therapy regimen containing at least 3 drugs which has been
             unchanged for at least 8 weeks prior to screening, and which is to be continued
             through Day 15 of the study.

          -  Be informed of the nature of the study and provide written informed consent.

          -  Be legally competent and able to communicate effectively with study personnel.

          -  Be able and willing to comply with outpatient visits.

        Exclusion Criteria:

          -  Presence of any acute illness within 14 days prior to study entry.

          -  Presence of any AIDS-related opportunistic infection (Category C according to the CDC
             Classification System for HIV-1 Infection, 1993 Revised Version) that is unstable in
             the Investigator's opinion or diagnosed in the 30 days prior to study entry.

          -  Patients who are, in the opinion of the Investigator, unable to comply with the dosing
             schedule and protocol evaluations.

          -  Patients with malabsorption syndromes affecting drug absorptions (e.g. Crohn's
             disease, chronic pancreatitis).

          -  Patients with systolic blood pressure < 90 mmHg or > 160 mmHg or diastolic blood
             pressure < 50 mmHg or > 110 mmHg.

          -  A history of seizures (excluding pediatric febrile seizures) or current administration
             of prophylactic anti-seizure medication for the indication of seizures or
             seizure-related conditions.

          -  A history of cerebrovascular accident (CVA) or transient ischemic attacks (TIA).

          -  Patients who have received radiation therapy or cytotoxic chemotherapeutic agents
             within 4 weeks prior to first dose of study drug.

          -  Patients who have received treatment with immunomodulating agents such as IL-2,
             alpha-interferon, beta-interferon, or gamma-interferon within 4 weeks prior to first
             dose of study drug.

          -  Receipt of an investigational drug or product, or participation in a drug study within
             a period of 30 days prior to receiving study medication.

          -  Bupropion-containing products require at least a 14-day washout period and will not be
             approved for co-administration.

          -  Rifampin or other rifamycin products require at least a 28-day washout period and will
             not be approved for coadministration.
Clinical trial NCT00093145 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: albumin-bound paclitaxel, carboplatin, herceptin®
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed adenocarcinoma of the breast

          -  Tumor shows 3+ overexpression of the human epidermal growth factor receptor 2
             (HER-2)/proto-oncogene by immunohistochemistry assay, or is fluorescence in situ
             hybridization (FISH)+

          -  Stage IV disease

          -  Measurable disease

          -  At least 3 weeks since prior cytotoxic chemotherapy

          -  At least 4 weeks since radiotherapy with full recovery

          -  At least 4 weeks since major surgery with full recovery

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  At least 18 years old

          -  Absolute neutrophil count (ANC) at least 1.5 x 10^9 cells/L

          -  Platelets at least 100 x 10^9 cells/L

          -  Hemoglobin at least 9 g/dL

          -  Aspartame aminotransferase (AST), alanine aminotransferase (ALT) less than 2.5X upper
             limit normal

          -  Alkaline Phosphatase less than 1.5X upper limit normal

          -  Creatinine less than 1.5 gm/dL

          -  Normal left ventricular ejection fraction

          -  Negative pregnancy test

          -  Agree to use method to avoid pregnancy

          -  Informed Consent is obtained

        Exclusion Criteria:

          -  Up to one regimen of prior neo-adjuvant or adjuvant chemotherapy is allowed. One year
             since Taxane and Herceptin treatment.

          -  Cumulative life-time dose of doxorubicin is greater than 360 mg/m^2

          -  Concurrent immunotherapy or hormonal therapy

          -  Parenchymal brain metastases, if present, must be documented to be clinically and
             radiographically stable for at least 6 months after treatment

          -  Serious intercurrent medical or psychiatric illness, including serious active
             infection

          -  History of congestive heart failure

          -  History of other malignancy within the last 5 years which could affect the diagnosis
             or assessment of breast cancer

          -  Patients who have received an investigational drug within the previous 3 weeks

          -  Patient is currently enrolled in another clinical study receiving investigational
             therapies

          -  Pregnant or nursing women
Clinical trial NCT00306891 (phase 2, status: completed)
Conditions: cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: cediranib, cediranib 30 - 90 mg
SMILES: COC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1, COC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of advanced solid tumour.

          -  Ability to eat a high fat breakfast

        Exclusion Criteria:

          -  Poorly controlled high blood pressure.

          -  History of significant gastrointestinal problems
Clinical trial NCT00036764 (phase 2, status: completed)
Conditions: recurrent melanoma, stage iv melanoma
ICD codes: G47.13, J01.41, K11.22, K12.0, N96, F33.8, G03.2, C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: ixabepilone
SMILES: [H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed stage IV melanoma

          -  At least 1 measurable lesion

               -  Greater than 20 mm by conventional techniques

               -  Greater than 10 mm by spiral CT scan

          -  Known brain metastases allowed if all of the following criteria are met:

               -  Radiologically stable for at least 6 weeks after completion of whole brain
                  radiotherapy

               -  Stable at time of study

               -  No mass effect present radiologically

               -  No concurrent steroids to control symptoms of brain metastases

          -  Performance status - ECOG 0-2

          -  Performance status - Karnofsky 60-100%

          -  At least 3 months

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Bilirubin normal

          -  AST/ALT no greater than 2.5 times upper limit of normal (ULN)

          -  Creatinine no greater than 1.5 times ULN

          -  No symptomatic congestive heart failure

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No prior severe allergic reactions (grade III or IV or grade II not responsive to
             steroids) to taxanes or medications containing Cremophor EL

          -  No pre-existing grade 2 or greater peripheral neuropathy

          -  No HIV-positive patients receiving combination antiretroviral therapy

          -  No other concurrent uncontrolled illness

          -  No ongoing or active infection

          -  No psychiatric illness that would preclude study

          -  Prior vaccine therapy allowed

          -  Prior immunotherapy (e.g., interleukin-2 or interferon) allowed

          -  Stratum I:

               -  No prior chemotherapy

          -  Stratum II:

               -  No more than 2 prior chemotherapy regimens (must have included dacarbazine or
                  temozolomide)

          -  See Disease Characteristics

          -  See Disease Characteristics

          -  Prior limb-perfusion therapy allowed (stratum II)

          -  No other concurrent investigational or commercial agents or therapies intended to
             treat malignancy

          -  No concurrent Hypericum perforatum
Clinical trial NCT00262834 (phase 2, status: completed)
Conditions: breast cancer, stage i breast cancer, stage ii breast cancer, stage iii breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: vorinostat
SMILES: ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  No prior or concurrent hormonal therapy for breast cancer

          -  Histologically confirmed breast cancer, stage I-III disease, scheduled to undergo
             definitive surgery or other primary treatment (e.g., preoperative/neoadjuvant systemic
             treatment) for breast cancer

          -  ECOG 0-2 OR Karnofsky 60-100%

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Bilirubin normal

          -  AST and ALT ≤ 2.5 times upper limit of normal

          -  PT ≤ 14 seconds

          -  Creatinine normal

          -  No symptomatic congestive heart failure

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No ongoing or active infection

          -  No psychiatric illness or social situation that would preclude study compliance

          -  No other uncontrolled intercurrent illness

          -  No history of allergic reaction attributed to compounds of similar chemical or
             biologic composition to vorinostat

          -  At least 30 days since prior hormone replacement therapy (e.g., estrogen and/or
             progestin)

          -  Concurrent vaginal hormone preparations (e.g., vagifem or estring) allowed

          -  No concurrent birth control pills

          -  No prior radiotherapy to the ipsilateral breast

          -  No prior or concurrent radiotherapy for breast cancer

          -  No prior or concurrent novel therapy for breast cancer

          -  At least 14 days since prior valproic acid or another histone deacetylase inhibitor

          -  No other concurrent investigational agents

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

          -  No other concurrent therapy for this cancer

          -  WBC ≥ 3,000/mm^3

        Exclusion criteria:

          -  Patients must not be recieving any other investigational agents

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to SAHA.

          -  Patients may not be taking valproic acid or another histone deacetylase inhibitor for
             at least 2 weeks prior to initiating SAHA.

          -  Women who are pregnant.
Clinical trial NCT00383149 (phase 2, status: completed)
Conditions: metastatic pancreatic cancer
ICD codes: C25.3
Drugs: ixabepilone, cetuximab
SMILES: [H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of pancreatic adenocarcinoma (locally advanced
             disease that is not surgically resectable, or distant metastatic disease)

          -  Participants must have measurable disease as per Response Evaluation Criteria In Solid
             Tumors (RECIST) guidelines

          -  Participants must not have received prior chemotherapy, immunotherapy or
             chemoradiotherapy for advanced pancreas cancer

          -  Karnofsky performance status (KPS) of 70-100

          -  Adequate hematologic, hepatic and renal function
Clinical trial NCT00636740 (phase 2, status: completed)
Conditions: hormone-refractory prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: zoledronic acid 20mg tablets, zoledronic acid, zoledronic acid 20mg tablets
SMILES: OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O, OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O, OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Prostate Cancer with rising PSA levels after hormone treatment and bone metastasis
             based on an X-ray.

        Exclusion Criteria:

          -  Already be on a bisphosphonate treatment (Zometa, Fosamax, Actonel)
Clinical trial NCT00584584 (phase 2, status: completed)
Conditions: allergic rhinitis
ICD codes: J30.89, J30.9, J30.2, J30.1, J30.5, J30.81
Drugs: qax576, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  History of allergic rhinitis.

        Exclusion Criteria:

          -  Respiratory disease other than mild intermittent asthma.

          -  Received immunotherapy in past 3 years.

          -  History of clinically significant drug allergy.

          -  History of clinical schistosomiasis or travel within 6 months prior to or following
             study to an area with endemic schistosomiasis.

          -  History of exposure to human therapeutic antibodies, immunoglobulins or other plasma
             products.

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00168883 (phase 2, status: unknown status)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: carboplatin, paclitaxel, vinorelbine
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Chemotherapy naive patients with histologically confirmed NSCLC stage III and IV

        Exclusion Criteria:

          -  New York Heart Association (NYHA) III or IV

          -  Brain metastases

          -  Neurotoxicity Grade 2 or greater
Clinical trial NCT00532129 (phase 2, status: completed)
Conditions: lymphocytic leukemia, chronic
ICD codes: C91.11, C91.12, C91.10
Drugs: rituximab, chlorambucil
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl
Eligibility criteria:

        Inclusion Criteria:

          -  previously untreated participants with cluster of differentiation 20 (CD20) positive
             B-cell chronic lymphocytic leukemia;

          -  participants with progressive Binet stage B, or C requiring therapy according to
             National Cancer Institute (NCI) criteria;

          -  Eastern Cooperative Oncology Group (ECOG) performance status <=2.

        Exclusion Criteria:

          -  previous treatment for Chronic Lymphocytic Leukaemia (CLL);

          -  known concomitant hematological malignancy;

          -  transformation to aggressive B-cell malignancy;

          -  history of severe cardiac disease;

          -  known hypersensitivity or anaphylactic reactions to murine antibodies.
Clinical trial NCT01077739 (phase 2, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: fluorouracil (5fu), leucovorin, bevacizumab [avastin], capecitabine [xeloda], oxaliplatin
SMILES: FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients >/=18 years of age

          -  metastatic colorectal cancer

          -  at least 1 measurable lesion according to RECIST v. 1.1

          -  patients with disease progression with prior FOLFIRI + Avastin therapy who are not
             candidates for primary metastasectomy

          -  disease progression </= 8 weeks after last dose of Avastin

          -  ECOG </=2

          -  No more than 8 weeks between 1st-line treatment with FOLFIRI + Avastin and 2nd-line
             treatment with XELOX or FOLFOX + Avastin

        Exclusion Criteria:

          -  disease progression > 8 weeks after last Avastin administration

          -  clinically significant cardiovascular disease

          -  CNS disease except for treated brain metastasis

          -  history of other malignancies within 2 years prior to start of study treatment (with
             the exception of curatively treated basal and squamous cell carcinoma of the skin or
             in situ carcinoma of the cervix)

          -  major surgery, open biopsy, or significant traumatic injury within 28 days prior to
             start of study treatment